NASDAQ:MLNDMillendo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Millendo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.18 -0.12 (-5.22 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$1.95Now: $2.18▼$2.3250-Day Range$1.47MA: $1.81▼$2.6652-Week Range$1.26Now: $2.18▼$15.75Volume1.35 million shsAverage Volume1.16 million shsMarket Capitalization$41.42 millionP/E RatioN/ADividend YieldN/ABeta1.53 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; and nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia. Millendo Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMillendo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Millendo Therapeutics has a potential upside of 404.6% from its current price of $2.18.Amount of Analyst CoverageMillendo Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesMillendo Therapeutics has received 68 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMillendo Therapeutics has received 76 “underperform” votes. (Add your “underperform” vote.)Community SentimentMillendo Therapeutics has received 52.78% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Millendo Therapeutics and other stocks. Vote “Outperform” if you believe MLND will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MLND will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMillendo Therapeutics does not currently pay a dividend.Dividend GrowthMillendo Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Millendo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Millendo Therapeutics is held by insiders.Percentage Held by Institutions66.40% of the stock of Millendo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Millendo Therapeutics are expected to grow in the coming year, from ($2.20) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Millendo Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Millendo Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMillendo Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.60 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLND Previous Symbol CUSIPN/A CIKN/A Webwww.millendo.com Phone734-845-9000Debt Debt-to-Equity Ratio0.04 Current Ratio5.76 Quick Ratio5.76Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales142.83 Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book0.66Profitability EPS (Most Recent Fiscal Year)($3.25) Net Income$-44,570,000.00 Net MarginsN/A Return on Equity-86.21% Return on Assets-68.49%Miscellaneous Employees37 Outstanding Shares19,000,000Market Cap$41.42 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:MLND Rates by TradingView Receive MLND News and Ratings via Email Sign-up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Millendo Therapeutics (NASDAQ:MLND) Frequently Asked Questions How has Millendo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Millendo Therapeutics' stock was trading at $6.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MLND shares have decreased by 66.9% and is now trading at $2.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Millendo Therapeutics? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Millendo Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Millendo Therapeutics. When is Millendo Therapeutics' next earnings date? Millendo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Millendo Therapeutics. How were Millendo Therapeutics' earnings last quarter? Millendo Therapeutics Inc (NASDAQ:MLND) posted its quarterly earnings results on Friday, May, 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.02. View Millendo Therapeutics' earnings history. What price target have analysts set for MLND? 7 Wall Street analysts have issued 12-month target prices for Millendo Therapeutics' stock. Their forecasts range from $2.00 to $26.00. On average, they expect Millendo Therapeutics' share price to reach $11.00 in the next twelve months. This suggests a possible upside of 404.6% from the stock's current price. View analysts' price targets for Millendo Therapeutics. Has Millendo Therapeutics been receiving favorable news coverage? News headlines about MLND stock have trended very positive on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Millendo Therapeutics earned a news impact score of 3.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutMillendo Therapeutics. Are investors shorting Millendo Therapeutics? Millendo Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 442,000 shares, an increase of 43.6% from the April 30th total of 307,900 shares. Based on an average trading volume of 800,300 shares, the short-interest ratio is presently 0.6 days. Approximately 3.4% of the shares of the company are sold short. View Millendo Therapeutics' Current Options Chain. Who are some of Millendo Therapeutics' key competitors? Some companies that are related to Millendo Therapeutics include CELYAD SA/ADR (CYAD), Sol Gel Technologies (SLGL), Galectin Therapeutics (GALT), Mustang Bio (MBIO), BIOFRONTERA AG/ADR (BFRA), Chembio Diagnostics (CEMI), Immunic (IMUX), Cerecor (CERC), Minerva Neurosciences (NERV), Sierra Oncology (SRRA), Rockwell Medical (RMTI), Harrow Health (HROW), Newron Pharmaceuticals (NWPHF), Conatus Pharmaceuticals (CNAT) and Arbutus Biopharma (ABUS). View all competitors. What other stocks do shareholders of Millendo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Millendo Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Applied Genetic Technologies (AGTC), Aileron Therapeutics (ALRN), Aquestive Therapeutics (AQST), Flexion Therapeutics (FLXN), Galmed Pharmaceuticals (GLMD), Gilead Sciences (GILD), Obseva (OBSV) and Outlook Therapeutics (OTLK). Who are Millendo Therapeutics' key executives? Millendo Therapeutics' management team includes the following people: Dr. Julia C. Owens Ph.D., CEO, Pres & Director (Age 47, Pay $702.8k)Mr. Louis J. Arcudi III, M.B.A., MBA, Chief Financial Officer (Age 59, Pay $495.79k)Dr. Ryan Zeidan Ph.D., Chief Devel. Officer (Age 40, Pay $511.69k)Dr. Gary Hammer M.D., Ph.D., Co-Founder and Chairman of Scientific Advisory BoardMs. Tamara Lynn Joseph, Gen. Counsel & Corp. Sec. (Age 57) What is Millendo Therapeutics' stock symbol? Millendo Therapeutics trades on the NASDAQ under the ticker symbol "MLND." Who are Millendo Therapeutics' major shareholders? Millendo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.23%), State Street Corp (0.94%), Soleus Capital Management L.P. (0.78%), Geode Capital Management LLC (0.75%), JPMorgan Chase & Co. (0.18%) and Bank of New York Mellon Corp (0.15%). Which major investors are selling Millendo Therapeutics stock? MLND stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC. Which major investors are buying Millendo Therapeutics stock? MLND stock was purchased by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., BlackRock Inc., Geode Capital Management LLC, Dupont Capital Management Corp, Los Angeles Capital Management & Equity Research Inc., Trexquant Investment LP, Nuveen Asset Management LLC, and Wedbush Securities Inc.. How do I buy shares of Millendo Therapeutics? Shares of MLND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Millendo Therapeutics' stock price today? One share of MLND stock can currently be purchased for approximately $2.18. How big of a company is Millendo Therapeutics? Millendo Therapeutics has a market capitalization of $41.42 million and generates $290,000.00 in revenue each year. The company earns $-44,570,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. Millendo Therapeutics employs 37 workers across the globe. What is Millendo Therapeutics' official website? The official website for Millendo Therapeutics is www.millendo.com. How can I contact Millendo Therapeutics? Millendo Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at 734-845-9000 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
